# EDGAR Filing Document

**Accession Number:** 0001860871
**File Stem:** 0001641172-25-016299
**Filing Date:** 2025-6
**Character Count:** 2482
**Document Hash:** f3cc4e7fb3db3fe0dd5a1d63af56a98f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-016299.hdr.sgml**: 20250725

**ACCESSION NUMBER**: 0001641172-25-016299

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250624

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tevogen Bio Holdings Inc.
- **CENTRAL INDEX KEY:** 0001860871
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981597194
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 15 INDEPENDENCE BOULEVARD, SUITE #210
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059
- **BUSINESS PHONE:** 646-807-8832

**MAIL ADDRESS:**
- **STREET 1:** 15 INDEPENDENCE BOULEVARD, SUITE #210
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Semper Paratus Acquisition Corp
- **DATE OF NAME CHANGE:** 20210505

**Tevogen Bio Holdings Inc.**

**15 Independence Boulevard, Suite #210**

**Warren, New Jersey 07059**

June 24, 2025

**<u>VIA EDGAR</u>**

United States Securities and Exchange Commission

100 F Street, NE

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Tevogen Bio Holdings Inc.** |
|  | **Registration Statement on Form S-3** |
|  | **Filed June 20, 2025** |
|  | **File No. 333-288218** |
|  | **Request for Acceleration of Effectiveness** |

---

To the addressee above:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Tevogen Bio Holdings Inc. hereby requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement on Form S-3 (the "Registration Statement") and declare the Registration Statement effective as of 4:30 p.m., Eastern Time, on June 26, 2025, or as soon thereafter as possible.

Please feel free to direct any questions or comments concerning this request to Nick Hoover of Hogan Lovells US LLP at (410) 659-2790, and once the Registration Statement has been declared effective, please notify Mr. Hoover by calling him at the same phone number.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| Tevogen Bio Holdings Inc. | Tevogen Bio Holdings Inc. |
| <br>*/s/ Ryan Saadi*  | <br>*/s/ Ryan Saadi*  |
| By: | <br> Ryan Saadi |
| Title: | Chief Executive Officer and Chairperson of the Board of Directors |

---